Investigating how SIN3a affects a key receptor in pulmonary arterial hypertension
Role of SIN3a in the epigenetic regulation of the Bone Morphogenetic Protein Receptor Type 2 in pulmonary arterial hypertension
This study is looking at how a protein called SIN3a affects another protein, BMPR2, which is important for keeping your lung blood vessels healthy, and it hopes to find new ways to help people with pulmonary arterial hypertension (PAH) by understanding how these proteins work together.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Medical College NIH-funded |
| Lab location | 1 site (Valhalla, United States) |
| Project ID | NIH-10914794 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of SIN3a in regulating the Bone Morphogenetic Protein Receptor Type 2 (BMPR2), which is crucial for maintaining healthy blood vessels in the lungs. By exploring the molecular mechanisms that lead to changes in BMPR2 expression, the study aims to uncover how these changes contribute to pulmonary arterial hypertension (PAH), a serious condition characterized by high blood pressure in the lungs. The research involves examining the epigenetic modifications that affect BMPR2 in pulmonary artery endothelial cells, which may provide insights into potential therapeutic targets for PAH. Patients may benefit from a better understanding of the disease mechanisms, potentially leading to new treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension or those at risk for developing this condition.
Not a fit: Patients with pulmonary arterial hypertension caused by factors unrelated to BMPR2 or SIN3a may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating pulmonary arterial hypertension.
How similar studies have performed: Previous studies have shown promising results in understanding the role of epigenetic factors in vascular diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Valhalla, United States
- New York Medical College — Valhalla, United States (Active)
Researchers
- Principal investigator: Bisserier, Malik — New York Medical College
- Study coordinator: Bisserier, Malik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.